DGAP-News: MorphoSys to Present at Upcoming Virtual Investor Conferences
In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval.
DGAP-News: MorphoSys AG / Key word(s): Conference MorphoSys to Present at Upcoming Virtual Investor Conferences (news with additional features) 02.06.2020 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, June 2, 2020 MorphoSys to Present at Upcoming Virtual Investor Conferences
Jefferies Healthcare Conference Goldman Sachs 41st Annual Global Healthcare Conference J.P. Morgan European Healthcare Conference JMP Hematology and Oncology Forum PDF versions of the presentations will be provided at www.morphosys.com. Links to available webcasts will be filed under www.morphosys.com/conference-calls.
Additional features: File: Media Release
02.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | [email protected] |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1061279 |
End of News | DGAP News Service |
|
1061279 02.06.2020